Outlook Therapeutics is trading 14.55% down in pre-market at $0.94 after announcing a $55.0 million underwritten public offering priced at $0.99 per share-and-warrant unit.
- The deal includes 55,555,556 shares and immediately exercisable warrants, creating substantial dilution pressure ahead of the LYTENAVA U.S. launch.
- Management warned that its approximately $11.2 million cash balance funds operations only into September.